LOXO-305, A Next Generation Reversible BTK Inhibitor, for Overcoming Acquired Resistance to Irreversible BTK Inhibitors

被引：61

作者：

Brandhuber, Barbara ^{[1
]}

Gomez, Eliana ^{[1
]}

Smith, Steven ^{[2
]}

Eary, Todd ^{[1
]}

Spencer, Stacey ^{[1
]}

Rothenberg, S. Michael ^{[1
]}

Andrews, Steven ^{[1
]}

机构：

[1] Loxo Oncol Inc, Boulder, CO USA

[2] Loxo Oncol Inc, San Francisco, CA USA

来源：

关键词：

BTK; acquired resistance; chronic lymphocytic leukemia; non-Hodgkin lymphoma;

D O I：

10.1016/j.clml.2018.07.081

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CLL-200

引用

页码：S216 / S216

页数：1